Home » PHARMEXA TO START GV1001 TRIAL
PHARMEXA TO START GV1001 TRIAL
Pharmexa has submitted an application to initiate a Phase II trial of Heptovax. The trial will begin in the third quarter of 2006 and will include up to 41 liver cancer patients.
The Heptovax trial is an open-label study evaluating the safety and efficacy of GV1001 in advanced hepatocellular carcinoma (liver cancer). The trial will enroll patients from three centers in Spain, France and Germany.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May